Trolamine (Biafine)

Phase 3Small molecule

WWest China Hospital

Trolamine (Biafine) is one of 17 small molecule programs targeting Dermatitis. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

DermatitisActive, not recruiting

VaginitisNot yet recruiting

DermatitisPreclinical

Active, not recruiting

VaginitisPhase 3

Not yet recruiting

Competition

Competitive Landscape

20 competitors in Dermatitis

#DrugCompanyPhaseTrials

Otezla

Amgen

Approved

1 2

Anzupgo

Daliresp

Nizoral

Kenalog

BBausch Health Americas, Inc.

Approved

—6

Cortef

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Rinvoq

1 8

JAK Inhibitor

FFred Hutchinson Cancer Center

Phase 2

1 9

Trolamine (Biafine)

WWest China Hospital

Phase 3

1 10

Acanya

Pfizer

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2030

Post-ApprovalNot yet recruiting

Vaginitis

NCT07492654

Clinical

Trials by Indication[1]

Dermatitis1 trial

Efficacy of Fullerene in Preventing Radiation Dermatitis in Patients With Head and Neck Cancer .

Completed·WWest China Hospital·N/A·NCT06484166·132 enrolled

Vaginitis1 trial

Clinical Study on the Prevention and Treatment of Radiation Vaginitis With Triethanolamine Cream

Not yet recruiting·FFujian Cancer Hospital·Phase 4·NCT07492654·238 enrolled

Nasopharyngeal Carcinoma1 trial

Comparison of Efficacy and Safety Between Medical Radiation Protectants (FORRAD®) and Trolamine (Biafine) for the Management of Radiation Dermatitis in Patients With Nasopharyngeal Carcinoma Receiving IMRT

Unknown status·YYun-fei Xia·Phase 2·NCT02729324·136 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Trolamine (Biafine). U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Trolamine (Biafine) compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Trolamine (Biafine). EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — West China Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: WWest China Hospital

Trolamine (Biafine)

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2030

Trials by Indication[1]

Dermatitis1 trial

Vaginitis1 trial

Nasopharyngeal Carcinoma1 trial

References

Drug Info

Quick Facts

Related News